Orchestra BioMed Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	30.56	19.78	9.94	20.34
Short-Term Investments	57.04	64	0.96	15.45
Cash & Cash Equivalents	87.6	83.79	10.9	35.79
Cash Growth	4.55%	668.95%	-69.56%	-
Receivables	0.1	0.1	0.12	0.17
Inventory	0.15	0.28	0.07	0.07
Other Current Assets	1.27	0.53	0.23	0.23
Total Current Assets	89.11	84.69	11.32	36.25
Property, Plant & Equipment	2.83	3.68	1.12	1.03
Long-Term Investments	2.5	2.5	0.4	0.19
Other Long-Term Assets	0.77	4.71	0.69	0.63
Total Long-Term Assets	6.1	10.88	2.21	1.84
Total Assets	95.21	95.57	13.53	38.09
Accounts Payable	2.9	3.97	2.03	1.77
Deferred Revenue	17.43	19.54	22.4	20.93
Current Debt	0.65	0.7	2	4
Other Current Liabilities	-9.77	-5.64	-14.19	-12.34
Total Current Liabilities	11.21	18.57	12.24	14.36
Long-Term Debt	1.04	11.17	3.67	5.46
Other Long-Term Liabilities	14.92	13.3	17.39	15.36
Total Long-Term Liabilities	15.96	24.47	21.07	20.82
Total Liabilities	27.17	43.04	33.31	35.18
Total Debt	1.69	11.87	5.67	9.46
Debt Growth	-85.79%	109.24%	-40.01%	-
Retained Earnings	-248.85	-199.73	-166.13	-143.11
Comprehensive Income	-0.01	-0.01	0	-0
Shareholders' Equity	68.04	52.53	-19.78	-48.54
Net Cash / Debt	85.91	71.92	5.22	26.33
Net Cash / Debt Growth	19.46%	1276.89%	-80.17%	-
Net Cash Per Share	2.59	4.80	0.59	13.08
Working Capital	77.91	66.12	-0.92	21.89
Book Value Per Share	2.05	3.50	-2.24	-24.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).